MaxCyte, Inc. (MXCT)
NASDAQ: MXCT · Real-Time Price · USD
3.490
+0.160 (4.80%)
Nov 20, 2024, 4:00 PM EST - Market closed
MaxCyte Revenue
MaxCyte had revenue of $8.16M in the quarter ending September 30, 2024, with 2.00% growth. This brings the company's revenue in the last twelve months to $45.60M, up 19.85% year-over-year. In the year 2023, MaxCyte had annual revenue of $41.29M, down -6.72%.
Revenue (ttm)
$45.60M
Revenue Growth
+19.85%
P/S Ratio
n/a
Revenue / Employee
$318,874
Employees
143
Market Cap
349.27M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 41.29M | -2.97M | -6.72% |
Dec 31, 2022 | 44.26M | 10.37M | 30.59% |
Dec 31, 2021 | 33.89M | 7.73M | 29.52% |
Dec 31, 2020 | 26.17M | 4.55M | 21.04% |
Dec 31, 2019 | 21.62M | 4.95M | 29.72% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Enhabit | 1.04B |
ZimVie | 451.29M |
Ginkgo Bioworks Holdings | 217.95M |
Amylyx Pharmaceuticals | 196.49M |
Valneva SE | 176.82M |
Kamada | 158.38M |
Alector | 61.51M |
Semler Scientific | 58.94M |
MXCT News
- 8 days ago - MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics - GlobeNewsWire
- 14 days ago - MaxCyte, Inc. (MXCT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance - GlobeNewsWire
- 21 days ago - MaxCyte to Participate in Two Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - MaxCyte Appoints Cynthia Collins to its Board of Directors - GlobeNewsWire
- 5 weeks ago - MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024 - GlobeNewsWire
- 6 weeks ago - MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer - GlobeNewsWire
- 6 weeks ago - Maxcyte: Reaching Financial Inflection With CASGEVY Ramp Up - Seeking Alpha